Antiflammin-2

Antiflammin-2 is a synthetic nonapeptide (HDMNKVLDL) derived from the amino acid residues 246–254 of Annexin A1 (formerly known as lipocortin-1). It was designed to mimic the anti-inflammatory and pro-resolving properties of Annexin A1 and glucocorticoids. The drug's mechanism of action involves acting as an agonist for the Formyl peptide receptor 2 (FPR2/ALX), which mediates the resolution of acute inflammation by inhibiting leukocyte trafficking and promoting neutrophil detachment from the endothelium. Although historically characterized as an inhibitor of phospholipase A2 (PLA2) and platelet-activating factor (PAF) synthesis, later studies have debated its direct inhibitory effect on PLA2 while confirming its role in receptor-mediated signaling pathways. Antiflammin-2 has been investigated primarily by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for the topical treatment of chronic plaque psoriasis and has shown preclinical potential in ocular inflammatory conditions like conjunctivitis.

Other names

HDMNKVLDLAntiflammin 2Antiflammin2Antiflammin-2Antiflammin-IIHis-Asp-Met-Asn-Lys-Val-Leu-Asp-Leu